Key facts
as of Oct 2026- Developer of a next-generation physiology assessment device intended to advance the diagnosis and treatment of heart ischemia.
- Medyria is valued at approximately $29.3M as of Oct 2026 (last reported valuation).
- It has raised $16.2M; the latest was Later Stage VC ($1.9M) in Jul 2025.
- Notable investors include Venture Kick, Verve Ventures, Zürcher Kantonalbank, Buenavista Equity Partners, Buenavista Equity Partners Portugal — 12 tracked in total.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$29.3M
Medyria's last reported valuation, Jul 2025. Nothing priced has surfaced since.
Free account
More of Medyria with a free account
- ·The complete investor list: 12 names
- ·Watch Medyria: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for Medyria are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About Medyria
Developer of a next-generation physiology assessment device intended to advance the diagnosis and treatment of heart ischemia. The company offers a comprehensive system capable of assessing full cardiovascular function and detecting early signs of ischemia, enabling healthcare professionals to intervene sooner and prevent progression to myocardial infarction.
- Sector
- Healthcare
- HQ
- Winterthur, Switzerland
- Founded
- 2012
- Employees
- 9
- Website
- medyria.com/
- Ownership
- Privately Held (backing)